Sarcoma News

Vimseltinib improved objective response rate compared with placebo for patients with tenosynovial giant cell tumor, according to topline data from the agent’s manufacturer.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

ASCO released a research statement outlining new recommendations regarding the appropriate assessment of ovarian toxicity in cancer clinical trials.

The FDA announced several regulatory actions the past few weeks.

Atezolizumab induced durable responses among more than one-third of patients with advanced alveolar soft part sarcoma, according to data published in The New England Journal of Medicine.

Damon Reed, MD, has been appointed inaugural head of the division of pediatric solid tumors at Memorial Sloan Kettering Cancer Center.

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.

The FDA announced several regulatory actions the past few weeks.

ASCO Chief Medical Officer Julie R. Gralow, MD, FACP, FASCO, urged members of Congress to take action on cancer drug shortages, which she described as the worst she has witnessed during her 30-year career in oncology.

CHICAGO — Healio | HemOnc Today gathered the best, brightest and boldest in oncology for its second annual Disruptive Innovators Awards.